Target Name: ZNF470
NCBI ID: G388566
Review Report on ZNF470 Target / Biomarker Content of Review Report on ZNF470 Target / Biomarker
ZNF470
Other Name(s): CZF-1 | ZN470_HUMAN | chondrogenesis zinc finger protein 1 | Chondrogenesis zinc finger protein 1 | zinc finger protein 470 | Zinc finger protein 470

Overview of ZNF470: A Non-Coding RNA Molecule and Its Role in Disease

ZNF470 (Zinc Finger Nucleotide), also known as CZF-1, is a non-coding RNA molecule that plays a crucial role in various cellular processes. It is a key regulator of gene expression and has been associated with various diseases, including neurodegenerative disorders , cancer, and autoimmune diseases. ZNF470 has also been identified as a potential drug target and biomarker for several diseases.

ZNF470 is a member of the ZNF family, which includes several similar non-coding RNAs that play a role in regulating gene expression. The ZNF family is characterized by the presence of a zinc finger domain, which is a conserved genetic motif that is involved in protein-coding and non-coding RNA regulation. ZNF470 contains a zinc finger domain that is similar to those found in other members of the ZNF family.

ZNF470 is expressed in various tissues and cells throughout the body, including the brain, spinal cord, and peripheral tissues. It has been shown to play a role in regulating gene expression and in the development and progression of several diseases. For example, ZNF470 has has been shown to be involved in the development of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its role in neurodegenerative diseases, ZNF470 has also been associated with the development of cancer. Studies have shown that ZNF470 can be overexpressed in various cancer types, including breast, ovarian, and colorectal cancer. This overexpression is associated with the development of cancer stem cells, which are cells that have the ability to differentiate into any cell type and are responsible for the development of many diseases.

Another potential application of ZNF470 as a drug target is its role in the regulation of inflammation. ZNF470 has been shown to play a role in the regulation of immune responses and has been associated with the development of autoimmune diseases. For example, studies have shown that ZNF470 is involved in the regulation of T cell responses and that its overexpression can lead to the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

In addition to its potential as a drug target and biomarker, ZNF470 has also been identified as a potential therapeutic approach for treating several other diseases. For example, studies have shown that ZNF470 can be used to treat neurodegenerative disorders by modulating the activity of neural stem cells. Additionally, ZNF470 has been shown to be involved in the regulation of gene expression and can be used to treat cancer by inhibiting its overexpression.

Overall, ZNF470 is a non-coding RNA molecule that plays a crucial role in various cellular processes. Its presence and overexpression have been associated with the development of several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. As a potential drug target and biomarker, ZNF470 is a promising target for the development of new therapies for these diseases. Further research is needed to fully understand the role of ZNF470 in disease and to develop effective treatments.

Protein Name: Zinc Finger Protein 470

Functions: May be involved in transcriptional regulation

The "ZNF470 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF470 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF471 | ZNF473 | ZNF473CR | ZNF479 | ZNF48 | ZNF480 | ZNF483 | ZNF484 | ZNF485 | ZNF486 | ZNF487 | ZNF488 | ZNF490 | ZNF491 | ZNF492 | ZNF493 | ZNF496 | ZNF497 | ZNF497-AS1 | ZNF500 | ZNF501 | ZNF502 | ZNF503 | ZNF503-AS1 | ZNF503-AS2 | ZNF506 | ZNF507 | ZNF510 | ZNF511 | ZNF512 | ZNF512B | ZNF513 | ZNF514 | ZNF516 | ZNF516-DT | ZNF517 | ZNF518A | ZNF518B | ZNF519 | ZNF519P3 | ZNF521 | ZNF524 | ZNF525 | ZNF526 | ZNF527 | ZNF528 | ZNF528-AS1 | ZNF529 | ZNF529-AS1 | ZNF530 | ZNF532 | ZNF534 | ZNF536 | ZNF540 | ZNF541 | ZNF542P | ZNF543 | ZNF544 | ZNF546 | ZNF547 | ZNF548 | ZNF549 | ZNF550 | ZNF551 | ZNF552 | ZNF554 | ZNF555 | ZNF556 | ZNF557 | ZNF558 | ZNF559 | ZNF559-ZNF177 | ZNF560 | ZNF561 | ZNF561-AS1 | ZNF562 | ZNF563 | ZNF564 | ZNF565 | ZNF566 | ZNF566-AS1 | ZNF567 | ZNF568 | ZNF569 | ZNF56P | ZNF57 | ZNF570 | ZNF571 | ZNF571-AS1 | ZNF572 | ZNF573 | ZNF574 | ZNF575 | ZNF576 | ZNF577 | ZNF578 | ZNF579 | ZNF580 | ZNF582 | ZNF582-DT